Influx Healthtech Ltd, has achieved a milestone by receiving the FSSAI Form II approval for the use of Magnesium Glycinate in tablet, capsule, and liquid preparations. This approval, granted by the FSSAI Scientific Committee, reinforces Influx Healthtech’s commitment to innovation and regulatory compliance.
Magnesium Glycinate is a highly bioavailable form of magnesium, known for its superior absorption and gentle impact on the digestive system. Magnesium Glycinate is not listed in the FSSAI Gazette, and Glycinate salts form do not appear in Schedule I of the FSSAI approved ingredient list. Therefore, any manufacturer seeking to produce formulations containing Magnesium Glycinate must obtain Form II special central approval from the FSSAI.
Achieving this approval offers a distinct advantage to its clients. As one of the few manufacturers with the capability to legally produce and market Magnesium Glycinate combinations, Influx now offers an expanded portfolio of magnesium-based formulations tailored to meet diverse health needs.
With this approval in hand, Influx is prepared to support brands looking to include Magnesium Glycinate in their product lines. Influx welcomes collaboration with partners and brands seeking to develop innovative magnesium glycinate formulations. This approval opens up new possibilities in product development.
For more information or to explore partnership opportunities, please contact our business development team at Influx Healthtech Ltd.